Hypertension
- Patient assessment- brief overview
- Guidelines
- Left Ventricular Hypertrophy
- Hypertension Trials
- Ambulatory and Home BP Monitoring
- Lifestyle Measures
- Resistant Hypertension
|
Hypertension- JNC7
The USA's JNC guidelines suggested the following classification of blood pressure:
- Normal- BP <120/80
- Prehypertension- BP 120-139/80-89
(the Europeans prefer to refer to those with BP of 120-129/80-84 as normal and those with higher pressures as "high-normal")
- Hypertension Stage I- BP 140-159/90-99
- Hypertension Stage II- >160/100
The following are regarded as some of the key messages of JNC7
- In individuals older than age 50 years, SBP is a more important CVD risk
factor than DBP.
- Beginning at 115/75 mm Hg, CVD risk doubles for each increment of
20/10 mm Hg throughout the BP range (the absolute increase in risk rises with age).
- Those who are normotensive at 55 years of age will have a 90% lifetime
risk of developing hypertension.
- Those with SBP 120 to 139 mm Hg or DBP 80 to 89 mm Hg should be
considered prehypertensive and require health-promoting lifestyle
modifications to prevent a progressive rise in blood pressure and CVD.
- Thiazide-type diuretics should be initial drug therapy for most, either alone
or combined with drugs from other classes.
- Certain specific high-risk conditions are compelling indications for the use
of other antihypertensive drug classes (angiotensin-converting enzyme
inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel
blockers).
- Two or more antihypertensive medications will be required to achieve goal
BP in most hypertensive patients.
- For patients with BP >20/10 mm Hg above the BP goal, initiation of
therapy using two agents, one of which will usually be a thiazide diuretic,
should be considered.
- Hypertension will be controlled only if patients are motivated to stay on
their treatment plan. Positive experiences, trust in the clinician, and
empathy improve patient motivation and satisfaction.
Hitesh Patel, Cardiologist
5th May, 2005
Reference:
Franco V et al. Review: Clinical Cardiology: New Frontiers. Hypertensive Therapy: Part I.Circulation. 2004;109:2953-2958.
Users should read this document on "copyright" and "conditions of use".
|
  |